Fig. 1.
Ga68-PSMA PET-CT maximum intensity projection (a, b) and axial (c, d) images. Pre (a, c) and 8 weeks post (b, d) Lu-177-PSMA therapy, images showed partial molecular response (> 30% decrease in highest SUVmax). This 69 years old prostate cancer patient earlier treated with multiple lines of anti-androgens and two lines of chemotherapy docetaxel and cabazitaxel. Pre and 8 weeks post Lu-177-PSMA therapy, PSA showed partial response (21.3 ng/ml vs 5.4 ng/ml)
